Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kairos Pharma, Ltd. Common Stock (NY:KAPA)

0.6679 -0.0071 (-1.05%)
Streaming Delayed Price Updated: 10:12 AM EST, Jan 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Kairos Pharma, Ltd. Common Stock

< Previous 1 2 3 Next >
TinyGemsBreaks – To Participate In DealFlow Discovery Conference
Via Investor Brand Network
News headline image
Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference
From Kairos Pharma, Ltd
Via Business Wire
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Receives Clinical Trials Arena Research and Development Award for Advanced Prostate Cancer
Via Investor Brand Network
News headline image
Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer
From Kairos Pharma, Ltd
Via Business Wire
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Highlights 2025 Milestones and Clinical Progress in CEO Letter to Shareholders
Via Investor Brand Network
News headline image
Kairos Pharma Provides Shareholder Update
From Kairos Pharma Ltd
Via Business Wire
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Reports Positive Interim Phase 2 Results for ENV-105 in Advanced Prostate Cancer
Via Investor Brand Network
News headline image
Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting
From Kairos Pharma, Ltd
Via Business Wire
News headline image
Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025
From Kairos Pharma, Ltd
Via Business Wire
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Reports Positive Interim Phase 2 Data for ENV105 in Prostate Cancer
Via Investor Brand Network
News headline image
Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year
From Kairos Pharma, Ltd
Via Business Wire
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) to Host KOL Event on Phase 2 ENV105 Prostate Cancer Trial
Via Investor Brand Network
News headline image
Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer
From Kairos Pharma, Ltd
Via Business Wire
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present at H.C. Wainwright Global Investment Conference
Via Investor Brand Network
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present Initial Phase 1 Data of ENV105 at World Lung Cancer Conference
Via Investor Brand Network
News headline image
Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025
From Kairos Pharma, Ltd
Via Business Wire
News headline image
Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From Kairos Pharma, Ltd
Via Business Wire
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present at H.C. Wainwright Global Investment Conference
Via Investor Brand Network
News headline image
Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025
From Kairos Pharma, Ltd
Via Business Wire
News headline image
Tech Momentum Surges as IPA, HIT, SNYR, PNPN.V, KAPA and Others Drive Investor Awareness – More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence Earnings
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Reports Positive Safety Results in Phase 2 Study of Prostate Cancer Drug ENV-105
Via Investor Brand Network
News headline image
Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer
From Kairos Pharma, Ltd
Via Business Wire
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Highlights Positive Preclinical Data for KROS101 at ASCO 2025
Via Investor Brand Network
News headline image
Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
From Kairos Pharma, Ltd
Via Business Wire
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) to Participate in D. Boral Capital Global Conference on May 14
Via Investor Brand Network
InvestorkNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present KROS 101 Data at 2025 ASCO Annual Meeting
Via Investor Brand Network
News headline image
Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
From Kairos Pharma, Ltd
Via Business Wire
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Secures DoD Grant to Advance Lung Cancer Biomarker Research
Via Investor Brand Network
News headline image
Kairos Pharma Ltd. Provides Letter to Stockholders
From Kairos Pharma, Ltd
Via Business Wire
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Secures DoD Grant to Advance Lung Cancer Biomarker Research
Via Investor Brand Network
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.